# Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

> **NCT05580588** · PHASE2 · TERMINATED · sponsor: **Shanghai Pharma Biotherapeutics USA Inc.** · enrollment: 14 (actual)

## Conditions studied

- Liposarcoma, Dedifferentiated

## Interventions

- **DRUG:** SPH4336

## Key facts

- **NCT ID:** NCT05580588
- **Lead sponsor:** Shanghai Pharma Biotherapeutics USA Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-31
- **Primary completion:** 2024-10-04
- **Final completion:** 2024-10-31
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less than anticipated.
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580588, "Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05580588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*